Form 4: Palvella Therapeutics Director Elaine J. Heron Acquires Stock Options

Director Elaine J. Heron of Palvella Therapeutics acquired 24,700 stock options on December 13, 2024, which vest over three years.

Summary

• Elaine J. Heron, a director at Palvella Therapeutics, acquired 24,700 stock options on December 13, 2024.
• The options have an exercise price of $13.60.
• These options will vest in 36 equal monthly installments, becoming fully exercisable after three years from the grant date.
• The options expire on December 13, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, which is generally positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a public company, often used as part of their compensation package and to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, aligning their interests with the long-term success of the company.
• The vesting schedule of 36 months is also typical for such grants, encouraging long-term commitment from the director.
• The exercise price of $13.60 is a specific value for this grant and would need to be compared to other similar grants to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

stock options, insider trading, director, Palvella Therapeutics, equity, vesting